- Conditions
- Rheumatoid Arthritis
- Interventions
- Filgotinib, Placebo to match filgotinib, csDMARDs
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 449 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 55
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 43
matching trials from the live ClinicalTrials.gov search.
- Conditions
- RA
- Interventions
- Sarilumab, Auto-Injector Device (AID), Pre-filled Syringe (PFS), Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine
- Drug · Device
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 31
- States / cities
- Huntsville, Alabama • Peoria, Arizona • Roseville, California + 25 more
- Conditions
- Breast Neoplasms, Breast Diseases, Metastatic Triple Negative Breast Cancer
- Interventions
- Leflunomide
- Drug
- Lead sponsor
- Joseph Sparano
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- ARAVA® 20 mg tablets, Leflunomide 20 mg Tablets
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002
- U.S. locations
- 2
- States / cities
- Saint Charles, Missouri • Houston, Texas
- Conditions
- Rheumatoid Arthritis
- Interventions
- Not listed
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Viruria, Viremia
- Interventions
- Leflunomide and orotic acid
- Drug
- Lead sponsor
- Changzheng-Cinkate
- Industry
- Eligibility
- Up to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 4 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- leflunomide, procarbazine hydrochloride
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 26 more
- Conditions
- Recurrent Lymphoproliferative Disorder, Refractory Lymphoproliferative Disorder
- Interventions
- Leflunomide
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Interventions
- Best Practice, Leflunomide, Placebo Administration
- Other · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Arthritis, Rheumatoid
- Interventions
- PRTX-100 at 1.5 mcg/kg, PRTX-100 at 3.0 mcg/kg, PRTX-100 at 6.0 mcg/kg, PRTX-100 at 12.0 mcg/kg, PRTX-100 at 240 mcg, Placebo, PRTX-100 at 420 mcg
- Drug
- Lead sponsor
- Protalex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Sarasota, Florida • Coeur d'Alene, Idaho + 5 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- etanercept, Placebo, DMARD Therapy
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 34 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Methotrexate, Abatacept, Adalimumab, Azathioprine, Baricitinib, Certolizumab, Etanercept, Golimumab, Hydroxychloroquine, Infliximab, Leflunomide, Minocycline, Rituximab, Sarilumab, Sulfasalazine, Tofacitinib
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2029
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Melanoma
- Interventions
- Vemurafenib, Leflunomide
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Smoldering Plasma Cell Myeloma
- Interventions
- Leflunomide, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Glioma, Sarcoma
- Interventions
- SU101
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis
- Interventions
- Methotrexate, Sulfasalazine, Leflunomide, Pamidronate, Zoledronic acid, Etanercept, Adalimumab, Certolizumab, Infliximab, Golimumab, NSAID
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2050
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Healthy
- Interventions
- Leflunomide 20 mg Tablets, ARAVA™ 20 mg Tablets
- Drug
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Acute Graft Versus Host Disease, Hematopoietic and Lymphoid System Neoplasm
- Interventions
- Cholestyramine, Leflunomide, Steroid Therapy
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Rheumatoid Arthritis
- Interventions
- Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 546 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 56
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
- Conditions
- COVID-19
- Interventions
- Leflunomide
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
- Interventions
- Biospecimen Collection, Cholestyramine, Computed Tomography, Diagnostic Imaging, Gemcitabine, Leflunomide, Magnetic Resonance Imaging
- Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Rheumatoid Arthritis
- Interventions
- Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
- Other · Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 114
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- MLTA3698A, adalimumab, leflunomide, methotrexate, placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Peoria, Arizona + 11 more